Advanced search
Publication Cover
Future Medicinal Chemistry Volume 4, 2012 - Issue 11
Submit an article Journal homepage
763
Views
0
CrossRef citations to date
0
Altmetric
Review

Histone Deacetylase Inhibitors In The Treatment Of Cancer: Overview And Perspectives

Giuseppe Giannini1 Medicinal Chemistry, Oncology, R&D, Corporate Sigma-Tau S.p.A, Via Pontina, km 30,400I-00040Pomezia, ItalyCorrespondence[email protected]
View further author information
,
Walter Cabri2 Preclinical Development, R&D, Corporate Sigma-Tau S.p.A, Via Pontina, km 30,400I-00040Pomezia, ItalyView further author information
,
Caterina Fattorusso3 Dipartimento di Chimica delle Sostanze Naturali, Università di Napoli, Via D. Montesano, 49I-80131Napoli, ItalyView further author information
&
Manuela Rodriquez4 Dipartimento di Scienze Farmaceutiche e Biomediche, Università di Salerno, Via Ponte don Melillo, I-84084Fisciano, ItalyView further author information
Pages 1439-1460 | Published online: 02 Aug 2012

References

  • Allfrey VG , FaulknerR, MirskyAE. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis.Proc. Natl Acad. Sci. USA51, 786–794 (1964).
  • Kleff S , AndrulisED, AndersonCW, SternglanzR. Identification of a gene encoding a yeast historic H4 acetyltransferase.J. Biol. Chem.270, 24674–24677 (1995).
  • Brownell JE , ZhouJ, RanalliTet al. Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation. Cell 84, 843–851 (1996).
  • Taunton J , HassigCA, SchreiberSL. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p.Science272, 408–411 (1996).
  • Tanner KG , LandryJ, SternglanzR, DenuJM. Silent information regulator 2 family of NAD- dependent histone/protein deacetylases generates a unique product, 1-O-acetyl-ADP-ribose.Proc. Natl Acad. Sci. USA97, 14178–14182 (2000).
  • Martin M , KettmannR, DequiedtF. Class IIa histone deacetylases: regulating the regulators.Oncogene26, 5450–5467 (2007).
  • Grant S , EasleyC, KirkpatrickP. Vorinostat.Nat. Rev. Drug Discov.6, 21–22 (2007).
  • Breslow M . Dimethyl sulfoxide to vorinostat development of this histone deacetylase inhibitor as an anticancer drug.Nat. Biotechnol.25, 84–90 (2007).
  • VanderMolen KM , McCullochW, PearceCJ, OberliesNH. Romidepsin: a natural product recently approved for cutaneous T-cell lymphoma.J. Antibiot.64, 525–531 (2011).
  • Boumber Y , Issa J-PJ. Epigenetics in cancer: what’s the future. Oncology25, 1–13 (2011).
  • Biel M , WascholowskiV, GiannisA. Epigenetic – an epicenter of gene regulation: histones and histone-modifying enzymes.Angew. Chem. Int. Ed. Engl.44, 3186–3216 (2005).
  • Mai A , MassaS, RotiliDet al. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med. Res. Rev. 3, 261–309 (2005).
  • Rodriquez M , AquinoM, BrunoI, De Martino G, Taddei M, Gomez-Paloma L. Chemistry and biology of chromatin remodeling agents: state of art and future perspective of HDAC inhibitors. Curr. Med. Chem.13, 1119–1139 (2006).
  • Petrella A , FontanellaB, CarratùA, BizzarroV, RodriquezM, ParenteL. Histone deacetylase inhibitors in the treatment of hematological malignancies.Mini Rev. Med. Chem.11, 519–527 (2011).
  • Kristeleit R , StimsonL, WorkmanP, AherneW. Histone modification enzymes: novel targets for cancer drugs.Expert Opin. Emerg. Drugs.9, 135–154 (2004).
  • Marks PA , RichonVM, MillerTA, KellyWK. Histone deacetylase inhibitors: new targeted anticancer drugs. In: Cancer: Principles and Practice of Oncology (7th Edition). DeVita VT Jr, Hellman S, Rosenberg SA (Eds). Lippincott Williams & Wilkins, Philadelphia, PA, USA, 439–445 (2005).
  • Peserico A , SimoneC. Physical and functional HAT/HDAC interplay regulates protein acetylation balance.J. Biomed. Biotechnol.371832 (2011).
  • Yang XJ , SetoE. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men.Nat. Rev. Mol. Cell Biol.9, 206–218 (2008).
  • de Ruijter AJ , van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J.370, 737–749 (2003).
  • Gregoretti IV , LeeYM, GoodsonHV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis.J. Mol. Biol.338, 17–31 (2004).
  • Marks PA . The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.Expert Opin. Investig. Drugs19, 1049–1066 (2010).
  • Yang XJ , GrégoireS. Class II histone deacetylases: from sequence to function, regulation and clinical implication.Mol. Cell. Biol.25, 2873–2884 (2005).
  • Glozak MA , SenguptaN, ZhangX, SetoE. Acetylation and deacetylation of non-histone proteins.Gene363, 15–23 (2005).
  • Kim SC , SprungR, ChenYet al. Substrates and functional diversity of lysine acetylation revealed by a proteomics survey. Mol. Cell 23, 607–618 (2006).
  • Witt O , DeubzerHE, MildeY, OehmeI. HDAC family: what are the cancer relevant targets?Cancer Lett.277, 8–21 (2009).
  • Lemoine M , YounesA. Histone deacetylase inhibitors in the treatment of lymphoma.Discov. Med.10, 462–470 (2010).
  • Dokmanovic M , ClarkeC, MarksPA. Histone deacetylase inhibitors: overview and perspectives.Mol. Cancer Res.5, 981–989 (2007).
  • Chang S , McKinseyTA, ZhangCL, RichardsonJA, HillJA, OlsonEN. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development.Mol. Cell. Biol.24, 8467–8476 (2004).
  • McKinsey TA , OlsonEN. Cardiac histone acetylation – therapeutic opportunities abound.Trends Genet.20, 206–213 (2004).
  • McKinsey TA , OlsonEN. Toward transcriptional therapies for the failing heart: chemical screens to modulate genes.J. Clin. Invest.115, 538–546 (2005).
  • Ng HH , BirdA. Histone deacetylases: silencers for hire.Trends Biochem. Sci.25, 121–126 (2000).
  • Legube G , TroucheD. Regulating histone acetyltransferases and deacetylases.EMBO Reports Rev.4, 944–947 (2003).
  • Rayman JB , TakahashiY E2F mediates cell cycle-dependent transcriptional repression in vivo by recruitment of an HDAC1/mSin3B corepressor complex. Genes Dev.16, 933–947 (2002).
  • Balciunaite E , SpektorA. Pocket protein complexes are recruited to distinct targets in quiescent and proliferating cells.Mol. Cell. Biol.25, 8166–8178 (2005).
  • Knoepfler PS , EisenmanRN. Sin meets NuRD and other tails of repression.Cell99, 447–450 (1999).
  • Lunyak VV , BurgessR, PrefontaineGGet al. Corepressor-dependent silencing of chromosomal regions encoding neuronal genes. Science 298, 1747–1752 (2002).
  • Fischle W , DequiedtF, HendzelMJet al. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/NCoR. Mol. Cell 9, 45–57 (2002).
  • Chan JK , SunL, YangXJ, ZhuG, WuZ. Functional characterization of an amino-terminal region of HDAC4 that possesses MEF2 binding and transcriptional repressive activity.J. Biol. Chem.278, 23515–23521 (2003).
  • Fischle W , DequiedtF, FillionM, HendzelMJ, VoelterW, VerdinE. Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo. J. Biol. Chem.276, 35826–35835 (2001).
  • Lahm A , PaoliniC, PallaoroMet al. Unraveling the Hidden Catalytic Activity of Vertebrate Class IIa Histone Deacetylases. Proc. Natl Acad. Sci. USA 104, 17335–17340 (2007).
  • Hockly E , RichonVM, WoodmanBet al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington’s disease. Proc. Natl Acad. Sci. USA 100, 2041–2046 (2003).
  • Bottomley MJ , Lo SurdoP, Di GiovinePet al. Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J. Biol. Chem.283, 26694–26704 (2008).
  • Beumer JH , TawbiH. Role of histone deacetylases and their inhibitors in cancer biology and treatment.Curr. Clin. Pharmacol.5, 196–208 (2010).
  • Marquard L , GjerdrumLM, ChristensenIJ, JensenPB, SehestedM, RalfkiaerE. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma.Histopathology53, 267–277 (2008).
  • Weichert W . HDAC expression and clinical prognosis in human malignancies.Cancer Lett.280, 168–176 (2009).
  • Taunton J , CollinsJL, SchreiberSL. Synthesis of natural and modified trapoxins, useful reagents for exploring histone deacetylase function.J. Am. Chem. Soc.118, 10412–10422 (1996).
  • Glaser KB , LiJ, PeaseLJet al. Differential protein acetylation induced by novel histone deacetylase inhibitors. Biochem. Biophys. Res. Commun. 325, 683–690 (2004).
  • Bertrand P . Inside HDAC with HDAC inhibitors.Eur. J. Med. Chem.45, 2095–2116 (2010).
  • Yadong C , HuifangL, WanquanTet al. 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur. J.Med. Chem. 44, 2868–2876 (2009).
  • Noureen N , KalsoomS, RashidH. Ligand based pharmacophore modelling of anticancer histone deacetylase inhibitors.Afr. J. Biotech.9, 3923–3931 (2010).
  • Richon VM , WebbY, MergerRet al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl Acad. Sci. USA 93, 5705–5708 (1996).
  • Butler LM , AgusDB, ScherHIet al. Suberoylanilide hydroxamic acid, an in vivo inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 60, 5165–5170 (2000).
  • Reuben RC , WifeRL, BreslowR, RifkindRA, MarksPA. A new group of potent inducers of differentiation in murine erythroleukemia cells.Proc. Natl Acad. Sci. USA73, 862–866 (1976).
  • Su GH , SohnTA, RyuB, KernSE. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of compound library.Cancer Res.60, 3137–3142 (2000).
  • Wong JC , HongR, SchreiberSL. Structural biasing elements for in-cell histone deacetylase paralog selectivity.J. Am. Chem. Soc.125, 5586–5587 (2003).
  • Hanessian S , VinciV, AuzzasL, MarziM, GianniniG. Exploring alternative Zn-binding groups in the design of HDAC inhibitors: squaric acid, N-hydroxylurea and oxazoline analogues of SAHA.Bioorg. Med. Chem. Lett.16, 4784–4787 (2006).
  • Hanessian S , AuzzasL, GianniniGet al. Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence. Bioorg. Med. Chem. Lett. 17, 6261–6265 (2007).
  • Kozikowski AP , TapadarS, LuchiniDN, KimKH, BilladeauDD. Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on the HDAC biology and antiproliferative activity.J. Med. Chem.51, 4370–4373 (2008).
  • Giannini G , MarziM, PezziRet al. N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase. Bioorg. Med. Chem. Lett. 19, 2346–2349 (2009).
  • Auzzas L , LarssonA, MateraRet al. Non-natural macrocyclic inhibitors of histone deacetylase: design, synthesis and activity. J. Med. Chem., 53, 8387–8399 (2010).
  • Zhang Y , FangH, FengJ, JiaY, WangX, XuW. Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities.J. Med. Chem.54, 5532–5539 (2011).
  • Tsuji N , KobayashiM, NagashimaK, WakisakaY, KoizumiK. A new antifungal antibiotic, trichostatin.J. Antibiot.29, 1–6 (1976).
  • Mori K , KosekiK. Synthesis of trichostatin A, a potent differentiation inducer of Friend-leukemic cells and its antipode.Tetrahedron44, 6013–6020 (1988).
  • Remiszewski SW , SambucettiLC, BairKWet al. N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of NVP-LAQ824. J. Med. Chem. 46, 4609–4624 (2003).
  • Li KW , WuJ, XingW, SimonJA. Total synthesis of the antitumor depsipeptide FR-901, 228.J. Am. Chem. Soc.118, 7237–7238 (1996).
  • Furumai R , MatsuyamaA, KobashiNet al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 62, 4916–4921 (2002).
  • Ueda H , NakajiamH, HoriYet al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromabacterium violaceum. J. Antibiot. 47, 301–310. (1994).
  • Closse A , HugueninR. Isolierung und Strukturaufklärung von Chlamydocin.Helv. Chim. Acta57, 533–545 (1974).
  • Gross ML , McCreryD, CrowFet al. The structure of the toxin from helminthosporium carbonum. Tetrahedron Lett. 23, 5381–5384 (1982).
  • Umehara K , NakaharaK, KijotoSet al. Studies on WF-3161, a new antitumor antibiotic. J. Antibiot. 36, 478–483 (1983).
  • Schmidt U , BeutlerU, LieberknechtA. Total synthesis of the antitumor antibiotic WF-3161.Angew. Int. Ed.28, 333–334 (1989).
  • Itazaki H , NagashimaK, SugitaKet al. Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents. J. Antibiot. 43, 1524–1532 (1990).
  • Kijima M , YoshidaM, SugitaK, HorinouchiS, BeppuT. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase.J. Biol. Chem.268, 22429–22435 (1993).
  • Darkin-Rattray SJ , GurnettAM, MyersRWet al. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc. Natl Acad. Sci. USA 93, 13143–13147 (1996).
  • Singh SB , ZinkDL, LieschJMet al. Structure and chemistry of apicidins, a class of novel cyclic tetrapeptides without a terminal α-keto epoxide as inhibitors of histone deacetylase with potent antiprotozoal activities. J. Org. Chem. 67, 815–825 (2002).
  • Colletti SL , MyersRW, Darkin-RattraySJet al. Broad spectrum antiprotozoal agents that inhibit histone deacetylase: structure-activity relationships of apicidin. Part 1. Bioorg. Med. Chem. Lett. 11, 107–111 (2001).
  • Colletti SL , MyersR W, Darkin-Rattray SJ et al. Broad spectrum antiprotozoal agents that inhibit histone deacetylase: structure-activity relationships of apicidin. Part 2. Bioorg. Med. Chem. Lett.11, 113–117 (2001).
  • Mori H , UranoY, AbeFet al. FR235222, a fungal metabolite, is a novel immunosuppressant that inhibits mammalian histone deacetylase (HDAC). I. Taxonomy, fermentation, isolation and biological activities. J. Antibiot. 56, 72–79 (2003).
  • Xie W , ZouB, PeiD, MaD. Total synthesis of cyclic tetrapeptide FR235222, a potent immunosuppressant that inhibits mammalian histone deacetylases.Org. Lett.7, 2775–2777 (2005).
  • Rodriquez M , TerraccianoS, CiniEet al. Total synthesis, NMR solution structure, and binding model of the potent histone deacetylase inhibitor FR235222. Angew. Chem. Int. Ed. Engl. 45, 423–427 (2006).
  • Gomez-Paloma L , BrunoI, CiniEet al. Design and synthesis of cyclopeptide analogues of the potent histone deacetylase inhibitor FR235222. ChemMedChem 2, 1511–1519 (2007).
  • Di Micco S , TerraccianoS, BrunoIet al. Molecular modeling studies toward the structural optimization of new cyclopeptide-based HDAC inhibitors modeled on the natural product FR235222. Bioorg. Med. Chem. 16, 8635–8642 (2008).
  • Suzuki T . Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives.J. Med. Chem.42, 3001–3003 (1999).
  • El-Beltagi HM , MartensACM, LelievedP, HarounEA, HagenbeekA. Acetyldinaline: a new oral cytostatic drug with impressive differential activity against leukemic cells and normal stem cell.Cancer Res.53, 3008–3014 (1993).
  • Vaisburg A , BernsteinN, FrechetteSet al. (2-amino-phenyl)-amides of omega-substituted alkanoic acids as new histone deacetylase inhibitors. Bioorg. Med. Chem Lett. 14, 283–287 (2004).
  • Frey RR , WadaCK, GarlandRBet al. Trifluoromethylketones as inhibitors of histone deacetylase. Bioorg. Med. Chem. Lett. 12, 3443–3447 (2002).
  • Vasudevan A , JiZ, FreyRRet al. Heterocyclic ketones as inhibitors of histone deacetylase. Biooorg. Med. Chem. Lett. 13, 3909–3913 (2003).
  • Galletti P , QuintavallaA, VentriciCet al. Azetidinones as zinc-binding groups to design selective HDAC8 inhibitors. ChemMedChem 4, 1991–2001 (2009).
  • Botta CB , CabriW, CiniEet al. Oxime amide as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity and computational evaluation. J. Med. Chem. 54, 2165–2182 (2011).
  • Ungerstedt JS , SowaY, XuWSet al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 102, 673–678 (2005).
  • Bolden JE , PeartMJ, RickyW, JohnstoneRW. Anticancer activities of histone deacetylase inhibitors.Nat. Rev. Drug Discov.5, 769–784 (2006).
  • Van Lint C , EmilianiS, VerdinE. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation.Gene Expr.5, 245–253 (1996).
  • Glaser KB , StaverMJ, WaringJF, StenderJ, UlrichRG, DavidsenSK. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines.Mol. Cancer Ther.2, 151–163 (2003).
  • Richon VM , SandhoffTW, RifkindRA, MarksPA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.Proc. Natl Acad. Sci. USA97, 10014–10019 (2000).
  • Xu Y . Regulation of p53 responses by posttranslational modifications.Cell Death Diff.10, 400–403 (2003).
  • Jin YH , JeonEJ, LiQLet al. Transforming growth factor -beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation. J. Biol. Chem. 279, 29409–29417 (2004).
  • Chi XZ , YangJO, LeeKYet al. RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD. Mol. Cell. Biol. 25, 8097–8107. (2005).
  • Yano T , ItoK, FukamachiHet al. The RUNX3 tumor suppressor upregulates Bim in gastric epithelial cells undergoing transforming growth factor betainduced apoptosis. Mol. Cell. Biol. 26, 4474–4488 (2006).
  • Rascle A , JohnstonJA, AmatiB. Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5.Mol. Cell. Biol.23, 4162–4173 (2003).
  • Wang LG , OssowskiL, FerrariAC. Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line.Oncogene23, 5175–5184 (2004).
  • Lee EM , ShinS, ChaHJet al. Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells. Int. J. Mol. Med. 24, 45–50 (2009).
  • Burgess A , RuefliA, BeamishHet al. Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 23, 6693–6701 (2004).
  • Zhang Y , AdachiM, KawamuraR, ImaiK. Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis.Cell Death Differ.13, 129–140. (2006).
  • Zhao Y , TanJ, ZhuangL, JiangX, LiuET, YuQ. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim.Proc. Natl Acad. Sci. USA102, 16090–16095 (2005).
  • Johnstone RW . Histone-deacetylase inhibitors: novel drugs for the treatment of cancer.Nat. Rev. Drug Discov.1, 287–299 (2002).
  • Insinga A , MonestiroliS, RonzoniSet al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat. Med. 11, 71–76 (2005).
  • Borbone E , BerlingieriMT, De Bellis F et al. Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. Oncogene29, 105–116 (2010).
  • D‘Acunto CW , CarratuA, RodriquezM, TaddeiM, ParenteL, PetrellaA. LGP1, a histone deacetylase inhibitor analogue of FR235222, sensitizes promyelocytic leukaemia U937 cells to TRAIL-mediated apoptosis.Anticancer Res.30, 887–894 (2010).
  • Petrella A , FestaM, ErcolinoSFet al. Annexin-1 downregulation in thyroid cancer correlates to the degree of tumour differentiation. Cancer Biol. Ther. 5, 643–647 (2006).
  • Garcia Pedrero JM , FernandezMP, MorganROet al. Annexin A1 down-regulation in head and neck cancer is associated with epithelial differentiation status. Am. J. Pathol., 164, 73–79 (2004).
  • D‘Acunto CW , FontanellaB, RodriquezM, TaddeiM, ParenteL, PetrellaA. Histone deacetylase inhibitor FR235222 sensitizes human prostate adenocarcinoma cells to apoptosis through up-regulation of Annexin A1.Cancer Lett.295, 85–91 (2010).
  • Petrella A , D‘AcuntoCW, RodriquezMet al. Effects of FR23S222, a novel HDAC inhibitor, in proliferation and apoptosis of human leukaemia cell lines: role of annexin A1. Eur. J. Cancer 44, 740–749 (2008).
  • Xu W , NgoL, PerezG, DokmanovicM, MarksPA. Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor.Proc. Natl Acad. Sci. USA103, 15540–15545 (2006).
  • Xu WS , ParmigianiRB, MarksPA. Histone deacetylase inhibitors: molecular mechanisms of action.Oncogene26, 5541–5552 (2007).
  • Drummond DC , NobleCO, KirpotinDB, GuoZ, ScottGK, BenzCC. Clinical development of histone deacetylase inhibitors as anticancer agents.Annu. Rev. Pharmacol. Toxicol.45, 495–528 (2005).
  • Atadja PW . HDAC inhibitors and cancer therapy, epigenetics and disease.Prog. Drug Res.67, 175–195 (2011).
  • Cimini D , MattiuzzoM, TorosantucciL, DegrassiF. Histone hyperacetylation in mitosis prevents sister chromatid separation and produces chromosome segregation defects.Mol. Biol. Cell14, 3821–3833 (2003).
  • Taddei A , MaisonC, RocheD, AlmouzniG. Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases.Nat. Cell. Biol.3, 114–120 (2001).
  • Dowling M , VoongKR, KimM, KeutmannMK, HarrisE, KaoGD. Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents.Cancer Biol. Ther.4, 197–206 (2005).
  • Robbins AR , JablonskiSA, YenTJet al. Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin. Cell Cycle 4, 717–726 (2005).
  • Ruefli AA , AusserlechnerMJ, BernhardDet al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc. Natl Acad. Sci. USA 98, 10833–10838 (2001).
  • Rosato RR , AlmenaraJA, GrantS. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.Cancer Res.63, 3637–3645 (2003).
  • Ellis L , HammersH, PiliR. Targeting tumor angiogenesis with histone deacetylase inhibitors.Cancer Lett.280, 145–153 (2009).
  • Jeong JW , BaeMK, AhnMYet al. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111, 709–720 (2002).
  • Deroanne CF , BonjeanK, ServotteSet al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21, 427–436 (2002).
  • Carew JS , GilesFJ, NawrockiST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.Cancer Lett.269, 7–17 (2008).
  • Liang D , KongX, SangN. Effects of histone deacetylase inhibitors on HIF-1.Cell Cycle5, 2430–2435 (2006).
  • Kong X , LinZ, LiangD, FathD, SangN, CaroJ. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor1 alpha.Mol. Cell. Biol.26, 2019–2028 (2006).
  • Qian DZ , KachhapSK, CollisSJet al. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res. 66, 8814–8821 (2006).
  • Naldini A , FilippiI, CiniE, RodriquezM, CarraroF, TaddeiM. Downregulation of Hypoxia-related Responses by Novel Antitumor Histone Deacetylase Inhibitors in MDAMB231 Breast Cancer Cells.Anticancer Agents Med. Chem.12(4), 407–413 (2011).
  • Kim SO , ChoiBT, Choi I-W et al. Anti-invasive activity of histone deacetylase inhibitors via the induction of Egr-1 and the modulation of tight junction-related proteins in human hepatocarcinoma cells. BMB Reports42, 655–660 (2009).
  • Qureshi IA , MehlerMF. Epigenetics, nervous system tumors, and cancer stem cells.Cancers3, 3525–3556 (2011).
  • Farrell A . A close look at cancer.Nat. Med.17, 262–265 (2011).
  • Marks PA , XuWS. Histone deacetylase inhibitors: potential in cancer therapy.J. Cell. Biochem.107, 600–608 (2009).
  • Haberland M , MontgomeryRL, OlsonEN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy.Nat. Rev. Genet.10, 32–42 (2009).
  • Wagner JM , HackansonB, LübbertM, JungM. Therapy in combination.Clin. Epigenet.1, 117–136 (2010).
  • Wang H , DymockBW. New patented histone deacetylase inhibitors.Expert Opin. Ther. Pat.19, 1727–1757 (2009).
  • Suzuki T . Explorative study on isoform-selective histone deacetylase inhibitors.Chem. Pharm. Bull.57, 897–906 (2009).
  • Ma X , EzzeldinHH, DiasioRB. Histone deacetylase inhibitors: current status and overview of recent clinical trials.Drugs69, 1911–1934 (2009).
  • Bantscheff M , HopfC, SavitskiMet al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat. Biotechnol. 29, 255–265 (2011).
  • La Thangue NB , KerrDJ. Predictive biomarkers: a paradigm shift towards personalized cancer medicine.Nat. Rev. Clin. Oncol.8, 587–596 (2011).
  • Fotheringham S , EppingMT, StimsonLet al. Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell 15, 57–66 (2009).
  • Khan O , FotheringhamS, WoodVet al. HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc. Natl Acad. Sci. USA 107, 6532–6537 (2010).
  • Jennifer LB ,Yongyao X, Susanne JS et al. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood109, 1123–1130 (2007).
  • Adcock IM . HDAC inhibitors as anti-inflammatory agents.Br. J. Pharmacol.150, 829–831 (2007).
  • Routy JP . Valproic acid: a potential role in treating latent HIV infection.Lancet366, 523–524 (2005).
  • Andrews KT , HaqueA, JonesMK. HDAC inhibitors in parasitic diseases.Immunol. Cell Biol.90, 66–77 (2012).
  • Fischer A , SananbenesiF, WangX, DobbinM, Tsai L-H. Recovery of learning and memory is associated with chromatin remodelling. Nature447, 178–182 (2007).
  • Chuang D -M, Leng Y, Marinova Z, Kim H-J, Chiu C-T. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci.32, 591–601 (2009).
  • Butler R , BatesGP. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders.Nat. Rev. Neurosci.7, 784–796 (2006).
  • Cao H , JungM, StamatoyannopoulosG. Hydroxamide derivatives of short chain fatty acid have erythropoietic activity and induce γ-gene expression in vivo. Exp. Hematol.33, 1443–1449 (2005).
  • Minetti GC , ColussiC, AdamiRet al. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat. Med. 12, 1147–1150 (2006).
  • Lin HS , HuCY, ChanHYet al. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br. J. Pharmacol. 150, 862–872 (2007).
  • Romagnani P , LasagniL, MazzinghiB, LazzeriE, RomagnaniS. Pharmacological modulation of stem cell function.Curr. Med. Chem.14, 1129–1139 (2007).
  • Khan O , La Thangue NB. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol. Cell Biol.90, 85–94 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.